Breaking NewsDailyHealthLatin AmericaWorld

Monoclonal Antibodies, Anti-Cancer Vaccines at FIHAV

Among the main products commercialized by CIMAB S.A., an exclusive representative of the Molecular Immunology Center (CIM), are monoclonal antibodies and therapeutic vaccines for cancer treatment.

With almost two decades of existence, this company, which is presenting its products at the Havana International Trade Fair, FIHAV 2011, is considered an important source of exports in Cuba.

The Recombinant Human Erythropoietin, a glycoprotein recommended for treating anemia patients by different causes as kidney failure or AIDS can be, was in the beginning the most sought after compound produced by the CIM, Norkis Arteaga, general manager of CIMAB S.A., told press.

One of them is CIMAher, trade name of the monoclonal antibody Nimotuzumab, a humanized immunoglobulin produced in the CIM. It has a powerful anti-angiogenic effect and is recommended in combination with radiotherapy in brain and neck tumor treatment in advanced studies, Arteaga said.

Another product is CimaVax-EGF, a therapeutic vaccine for the treatment of lung cancer in non-small cells in advanced stages, he noted.

Other biological products to fight different kinds of breast, uterine cervix, and colorectal cancer, and diseases such as rheumatoid arthritis are in different stages of study in the CIM, the expert stated.

FIHAV 2011 was opened from Oct. 31 to Nov. 4 at the ExpoCuba exhibition site, in the presence of representatives from 57 nations.

Show More

Related Articles

One Comment

Back to top button
Breaking News
%d bloggers like this: